RxDoctor Payments DataLook up a doctor →

Janice Keating, MD

Neurology · Fort Smith, ARNPI 1982623708

Payments from drug & device makers

$16,056in general payments, 2019–2025

Across 1,021 payments — averaging $15.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novartis$2K
  • SK Life Science, Inc.$1K
  • UCB, Inc.$930
  • Amgen$912
  • Pfizer$853
  • plus $8K from 51 others

What the payments were for

  • Speaking & faculty fees$1681%
  • Food & beverage$15,88699%
  • Education$20%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)135$2,434
Novartis114$1,878
SK Life Science, Inc.60$1,092
UCB, Inc.60$930
Amgen42$912
Pfizer60$853
Biogen47$833
Neurocrine Biosciences, Inc.42$652
Acadia Pharmaceuticals Inc28$471
Lundbeck LLC23$421
Eisai Inc.26$411
MDD US Operations, LLC18$388
Sanofi22$330
Amneal Pharmaceuticals LLC20$318
Sunovion Pharmaceuticals Inc.24$292
EMD Serono, Inc.24$279
Avanir Pharmaceuticals, Inc.19$262
AstraZeneca(2 entities)13$236
Argenx US, Inc.11$201
Lilly USA, LLC13$198
Supernus Pharmaceuticals, Inc.50$193
Biohaven Pharmaceutical Holding Company Ltd.23$188
Teva Pharmaceuticals USA, Inc.11$186
Adamas Pharmaceuticals, Inc.14$172
Acorda Therapeutics, Inc9$168
Livanova USA, Inc.5$150
Tanabe Pharma America, Inc.9$138
Biohaven Pharmaceuticals, Inc.12$136
Kyowa Kirin, Inc.8$124
Neurelis, Inc.7$113
Catalyst Pharmaceuticals, Inc.6$112
Genentech USA, Inc.5$81
Takeda Pharmaceuticals U.S.A., Inc.9$81
Banner Life Sciences, LLC4$72
Otsuka America Pharmaceutical, Inc.4$68
Upsher-smith Laboratories LLC4$67
Jazz Pharmaceuticals Inc.4$59
Bristol Myers Squibb3$57
ANI Pharmaceuticals, Inc.2$53
Mallinckrodt Enterprises LLC3$51
Johnson & Johnson3$46
Grifols USA, LLC2$45
Merz Pharmaceuticals, LLC2$38
Corium, LLC4$38
Axsome Therapeutics, Inc.2$33
TG Therapeutics, Inc.1$33
GE HealthCare1$27
Zyla Life Sciences, Inc.2$24
Averitas Pharma Inc.1$24
Arbor Pharmaceuticals, Inc.1$18
Avion Pharmaceuticals1$17
Abbott1$14
Alnylam Pharmaceuticals Inc.1$13
Greenwich Biosciences, Inc.1$13
GRT US Holding, Inc.1$7
Sumitomo Pharma America, Inc.3$5
Kinex Medical Company LLC1$2

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,056 in reported general payments places this provider in the 75th percentile of 93 neurology providers in Arkansas.

See all neurology providers in Arkansas

Medicare billing

Part B allowed, 2024
$168,325
Medicare patients
665
Services billed
6,485

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab52$506,652
Vigabatrin13$253,781
BetaseronInterferon Beta-1b15$145,841
Aimovig AutoinjectorErenumab-Aooe150$120,969
RytaryCarbidopa/Levodopa84$95,354
BotoxOnabotulinumtoxina66$79,950
Teriflunomide16$75,249
CopaxoneGlatiramer Acetate11$67,534
Dimethyl Fumarate39$59,767
Nurtec OdtRimegepant Sulfate44$55,598
BriviactBrivaracetam26$48,233
Glatiramer Acetate14$46,569
AptiomEslicarbazepine Acetate16$40,267
FycompaPerampanel30$32,590
GlatopaGlatiramer Acetate16$32,062

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox, Ubrelvy$2,434$105,37384 claims
Amneal Pharmaceuticals LLCRytary$318$95,35484 claims
Teva Pharmaceuticals USA, Inc.Copaxone$186$67,53411 claims
UCB, Inc.Briviact, Vimpat$930$60,89537 claims
PfizerNurtec Odt$853$55,59844 claims
Sunovion Pharmaceuticals Inc.Aptiom$292$40,26716 claims
Eisai Inc.Fycompa$411$32,59030 claims
Neurelis, Inc.Valtoco$113$14,89921 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 93 neurology providers in Arkansas.

Other neurology in Fort Smith

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →